Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/07/2003US20030149011 Methods and reagents for extracorporeal immunomodulatory therapy
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149009 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
08/07/2003US20030149008 Hormonal implants treatment of the breast cancer
08/07/2003US20030149007 For inducing bronchodilation or providing relief of bronchospasm
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149003 Functionalized stilbene derivatives as improved vascular targeting agents
08/07/2003US20030149002 Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030149000 Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
08/07/2003US20030148998 Glucosamine and method of making glucosamine from microbial biomass
08/07/2003US20030148997 Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
08/07/2003US20030148996 For therapy of undesirable or uncontrolled cell proliferation
08/07/2003US20030148994 Useful as a surgical hemostat
08/07/2003US20030148993 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
08/07/2003US20030148991 Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders
08/07/2003US20030148990 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
08/07/2003US20030148987 Selective 11beta-HSD inhibitors and methods of use thereof
08/07/2003US20030148986 For therapy of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148981 Administering a therapeutic formulation containing the phosphorothioate oligonucleotide and at least one cyclodextrin to the mammal; monitoring the immune response of mammal
08/07/2003US20030148976 For therapy of cancer, infectious disease, and allergic disorders
08/07/2003US20030148974 Antisense modulation of akt-3 expression
08/07/2003US20030148970 Contacting the cell with an antisense oligonucleotide complementary to a region of RNA that encodes a portion of HDAC-4 (histone deacetylase) 4, whereby HDAC-4 activity is inhibited
08/07/2003US20030148967 For prophylaxis and therapy of viral infection for example by varicella zoster virus (VZV)
08/07/2003US20030148966 For suppressing necrosis in cells
08/07/2003US20030148964 Single dose azithromycin
08/07/2003US20030148963 Use of etoposide at the manufacture of pharmaceutical formulations intended for the treatment of inflammations in mammals, including humans
08/07/2003US20030148962 For therapy of ischemic cerebral-vascular diseases
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148949 Administering a trefoil peptide or biologically active fragment thereof to a skin lesion or region of the skin where a lesion is to be prevented; wound healing agents which can speed healing, reduce pain and delay/prevent lesions
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148941 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
08/07/2003US20030148931 A drug delivery system (DDS) compound of a carboxylated polysaccharide derivative bonded to a camptothecin derivative with or with out a oligopeptide a spacer; storage stability; preservation; side effect reduction; antitumor agents
08/07/2003US20030148926 Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
08/07/2003US20030148925 Insulin formulation for inhalation
08/07/2003US20030148890 Organic compounds
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030148511 Induction of immunity using inhibitors of granzymes
08/07/2003US20030148451 Endothelial differntiation gene 6-like g protein coupled receptor
08/07/2003US20030148414 Comprises extracellular bacterial autoinducer-2 signalling molecule (such as 4,5-dihydroxy-2,3-pentanedione or homocysteine) which stimulates LuxQ bioluminescent proteins/ genes in Vibrio harveyi operon bioassay
08/07/2003US20030148408 Compositions and methods for the diagnosis and treatment of tumor
08/07/2003US20030148398 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148385 Vitro model for priocidal activity
08/07/2003US20030148376 Secreted and transmembrane polypeptides and nucleic acids encoding the same
08/07/2003US20030148373 Comprises nucleotide sequences coding membrane protein/pro-polypeptide; antitumor agents; drug screening
08/07/2003US20030148327 Nucleic acid of given sequence; oligonucleotides and oligomers for detecting the cytosine methylation of genes; tumors and cancer
08/07/2003US20030148326 Diagnosis of diseases associated with dna transcription
08/07/2003US20030148294 DNA encoding novel chemokine receptors
08/07/2003US20030148259 Calcium Induced Calcium Release (CICR) in beta-cells as a novel target for stimulating insulin secretion in a glucose dependent manner; drug screening; treating type 2 diabetes with pyrido(3,4-b)indole compounds
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147981 Dosage is determined on the basis of an individual factor and a stress index. The individual factor is based on a weight factor of the individual, an age factor of the individual and a training factor of the individual. The training factor is
08/07/2003US20030147979 Ligand for peroxisome proliferator-activated receptor
08/07/2003US20030147975 Pharmaceutical composition which produces irritation
08/07/2003US20030147973 The use of extracts and compounds derived from the plant Aristolochia taliscana and their analogues in the treatment of AIDS.
08/07/2003US20030147970 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
08/07/2003US20030147969 Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
08/07/2003US20030147967 Apparatus and method for preparing microparticles
08/07/2003US20030147966 Nanoparticle delivery vehicle
08/07/2003US20030147964 Storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres for sustained release and
08/07/2003US20030147959 Alpha-tocopherol, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans various routes is disclosed. Polyoxyethylene
08/07/2003US20030147957 An inner core formulated for controlled release comprising a mixture of a granulated admixture of a decarboxylase inhibitor and a surfactant, and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof;immediate release
08/07/2003US20030147955 Dry .1 to 1.5% tamsulosin active material and excipients; treating benign prostatic hyperplasia
08/07/2003US20030147952 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
08/07/2003US20030147951 Tablet composition
08/07/2003US20030147950 .1-10 mg of tamsulosin with an enteric coating and has a dissolution profile in media of </= 60% at 2 hours; reduced or no food effect
08/07/2003US20030147948 Composition comprises sustained-release fine particles and manufacturing method thereof
08/07/2003US20030147947 Orodispersible solid pharmaceutical form
08/07/2003US20030147945 Vehicles stably associated with non-antagonistic combinations of >/= 2 synergistic agents
08/07/2003US20030147943 Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
08/07/2003US20030147942 Pharmaceutical gel composition
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147936 Prostatic hormonal implants treatment of prostate cancer
08/07/2003US20030147930 Antibiotic, functional cosmetic and functional food containing levulinic acid and their derivatives
08/07/2003US20030147927 Eutectic-based self-nanoemulsified drug delivery system
08/07/2003US20030147926 Compositions and methods for transdermal oxybutynin therapy
08/07/2003US20030147920 RC-529 (the glucosamine phosphate compound) and QS-21 (a saponin); synergistic mixture; vaccines; treating cancer, microbial infections and autoimmune disorders
08/07/2003US20030147902 Method of stimulating and immune response by administration of host organisms that express intimin alone of as a fusion protein with one of more other antigens
08/07/2003US20030147899 Endogenous hormone adjuvant and uses thereof
08/07/2003US20030147887 B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
08/07/2003US20030147884 Administering a breast cancer patient (caused by human ErbB2 oncogene which codes a transmebrane glycoprotein receptor related to epidermal growth factor receptor, is overexpressed) an anti ErbB2 antibody and a drug
08/07/2003US20030147861 Compounds and methods for the modulation of immune responses
08/07/2003US20030147860 A mixture of animal growth factors, hyaluronic acid, chitosan or chitosan derivatives for treating bone disorders or filling a bone defect
08/07/2003US20030147848 Administering a desulfated heparin to a patient with acute, subacute or chronic inflammation, while the relative N-sulfate content of the N-desulfated heparins is 0.1-99.9%
08/07/2003US20030147845 O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
08/07/2003US20030147844 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials
08/07/2003US20030147823 Using a cyclopentane compound
08/07/2003US20030147815 Administering tri-(or tetra-)iodothyropropionic acid
08/07/2003US20030147813 Method for treating chronic myelogenous leukemia
08/07/2003US20030147807 Water soluble paclitaxel derivatives
08/07/2003US20030146922 System and method for diminished reality
08/07/2003CA2813048A1 Composition for use in treating patients suffering from movement disorder
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2514518A1 Process for the preparation of a nutrient formulation
08/07/2003CA2475003A1 Double-stranded oligonucleotides
08/07/2003CA2474958A1 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003CA2474951A1 Production of .delta.9 tetrahydrocannabinol
08/07/2003CA2474910A1 Oligonucleotide compositions with enhanced efficiency
08/07/2003CA2474871A1 Furanone derivatives
1 ... 5383 5384 5385 5386 5387 5388 5389 5390 5391 5392 5393 5394 5395 5396 5397 5398 5399 5400 5401 5402 5403 ... 7860